INLIGHT trial fallout: Wave Life Sciences shares plunged over 40% following the release of six-month data from the Phase 1 INLIGHT trial for its obesity candidate WVE-007. Social media buzzed with disappointment over the minimal placebo-adjusted weight loss of just 1%, far short of expectations set by blockbuster GLP-1 therapies. Investors highlighted the stark contrast to rivals' impressive pound-shedding results.
Body composition debate: Despite the setback, some discussions praised reductions in visceral fat by 14% and preservation of lean mass after a single dose. Posters noted potential advantages in body composition over GLP-1s, sparking talks of combo strategies or cardiometabolic pivots. Yet, the market's verdict was clear: overall weight loss remains king.
RNA sector ripples: The data cast doubts on RNA therapeutics' viability in obesity, with chatter questioning program continuation. Optimists pointed to validated biology benefiting peers, but bearish tones dominated amid the stock's rout. Broader implications for the biotech space fueled heated exchanges.
Note: This discussion summary was generated from an AI condensation of post data.
Wave Life Sciences Insider Trading Activity
Wave Life Sciences insiders have traded $WVE stock on the open market 49 times in the past 6 months. Of those trades, 6 have been purchases and 43 have been sales.
Here’s a breakdown of recent trading of $WVE stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 5 purchases buying 8,773,496 shares for an estimated $54,631,065 and 0 sales.
- PLC GSK purchased 1,470,000 shares for an estimated $27,930,000
- CHRIS FRANCIS (See Remarks) has made 0 purchases and 14 sales selling 485,483 shares for an estimated $7,102,264.
- KYLE MORAN (Chief Financial Officer) has made 0 purchases and 7 sales selling 263,624 shares for an estimated $4,152,237.
- AIK NA TAN has made 0 purchases and 8 sales selling 134,218 shares for an estimated $1,823,158.
- CHRISTIAN O HENRY has made 0 purchases and 4 sales selling 93,445 shares for an estimated $1,369,323.
- ADRIAN RAWCLIFFE has made 0 purchases and 2 sales selling 58,115 shares for an estimated $739,420.
- GREGORY L. VERDINE has made 0 purchases and 2 sales selling 20,000 shares for an estimated $269,460.
- MARK CORRIGAN has made 0 purchases and 2 sales selling 16,115 shares for an estimated $217,297.
- HEIDI L WAGNER has made 0 purchases and 2 sales selling 14,000 shares for an estimated $189,000.
- PAUL BOLNO (President and CEO) sold 10,480 shares for an estimated $140,956
- CHANDRA VARGEESE (See Remarks) sold 3,228 shares for an estimated $43,416
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Wave Life Sciences Hedge Fund Activity
We have seen 144 institutional investors add shares of Wave Life Sciences stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 10,005,609 shares (+195.0%) to their portfolio in Q4 2025, for an estimated $170,095,353
- DARWIN GLOBAL MANAGEMENT, LTD. added 7,298,421 shares (+inf%) to their portfolio in Q4 2025, for an estimated $124,073,157
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,362,880 shares (+83.1%) to their portfolio in Q4 2025, for an estimated $57,168,960
- BELLEVUE GROUP AG removed 2,603,940 shares (-63.6%) from their portfolio in Q4 2025, for an estimated $44,266,980
- KYNAM CAPITAL MANAGEMENT, LP removed 2,390,948 shares (-52.4%) from their portfolio in Q4 2025, for an estimated $40,646,116
- BLACKROCK, INC. added 2,218,094 shares (+21.3%) to their portfolio in Q4 2025, for an estimated $37,707,598
- PRIMECAP MANAGEMENT CO/CA/ added 2,196,632 shares (+115.7%) to their portfolio in Q4 2025, for an estimated $37,342,744
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Wave Life Sciences Analyst Ratings
Wall Street analysts have issued reports on $WVE in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
- Oppenheimer issued a "Outperform" rating on 12/16/2025
- Wedbush issued a "Outperform" rating on 12/12/2025
- B. Riley Securities issued a "Buy" rating on 12/12/2025
- Clear Street issued a "Buy" rating on 12/09/2025
- Citigroup issued a "Buy" rating on 12/09/2025
- Canaccord Genuity issued a "Buy" rating on 12/09/2025
To track analyst ratings and price targets for Wave Life Sciences, check out Quiver Quantitative's $WVE forecast page.
Wave Life Sciences Price Targets
Multiple analysts have issued price targets for $WVE recently. We have seen 13 analysts offer price targets for $WVE in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Alec Stranahan from B of A Securities set a target price of $21.0 on 03/27/2026
- Benjamin Burnett from Wells Fargo set a target price of $13.0 on 03/27/2026
- Salim Syed from Mizuho set a target price of $27.0 on 03/25/2026
- Whitney Ijem from Canaccord Genuity set a target price of $52.0 on 03/10/2026
- Yun Zhong from Wedbush set a target price of $35.0 on 03/06/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $30.0 on 03/02/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $41.0 on 02/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
